Gene-expression patterns predict phenotypes of immune-mediated thrombosis.

Antiphospholipid antibody syndrome (APS) is a complex autoimmune thrombotic disorder with defined clinical phenotypes. Although not all patients with elevated antiphospholipid antibody (aPLA) levels develop complications, the severity of these potential events mandates aggressive and extended lifelong anti-thrombotic therapy. One hundred twenty-nine patients (57 patients with APS and venous thromboembolism [VTE], 32 patients with VTE without aPLA, 32 patients with aPLA only, and 8 healthy patients) were enrolled. RNA from peripheral-blood collection was used for DNA microarray analysis. Patterns of gene expression that characterize APS as well as thrombosis in the presence of aPLA were identified by hierarchical clustering and binary regression methods. Gene-expression profiles identify and predict individuals with APS from patients with VTE without aPLA. Importantly, similar methods identified expression profiles that accurately predicted those patients with aPLA at high risk for thrombotic events. All profiles were validated in independent cohorts of patients. The ability to predict APS, but more importantly, those patients at risk for venous thrombosis, represents a paradigm for a genomic approach that can be applied to other populations of patients with venous thrombosis, providing for more effective clinical management of disease, while also reflecting the possible underlying biologic processes.

[1]  M. West,et al.  Gene expression predictors of breast cancer outcomes , 2003, The Lancet.

[2]  M. Hamberg,et al.  Arachidonic acid metabolism in the human mast cell line HMC-1: 5-lipoxygenase gene expression and biosynthesis of thromboxane. , 1995, Biochimica et biophysica acta.

[3]  J. Sánchez-Guerrero,et al.  Antiphospholipid Antibodies and the Antiphospholipid Syndrome in Systemic Lupus Erythematosus A Prospective Analysis of 500 Consecutive Patients , 1989, Medicine.

[4]  T. Barbui,et al.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor , 1990, The Lancet.

[5]  P. Hogg,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Lupus Anticoagulants Form Immune Complexes With Prothrombin and Phospholipid That Can Augment Thrombin Production in Flow , 2016 .

[6]  R. Derksen,et al.  Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? , 1993 .

[7]  T. Ortel,et al.  Prothrombin and β2-glycoprotein I frequently contribute to antiphospholipid antibody interactions with phospholipids and the generation of abnormal waveform profiles in coagulation assays , 2003, Thrombosis and Haemostasis.

[8]  J. Merrill,et al.  Genetics of antiphospholipid syndrome , 2004, Current rheumatology reports.

[9]  C. Chesterman,et al.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[10]  T. Sumida,et al.  Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. , 1992, Journal of immunology.

[11]  W. Robinson,et al.  Millennium Award Recipient Contribution Proteomics for the Development of Dna Tolerizing Vaccines to Treat Autoimmune Disease , 2022 .

[12]  R. Roubey,et al.  From antiphospholipid syndrome to antibody-mediated thrombosis , 1997, The Lancet.

[13]  J. Matsuda,et al.  Anti‐annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody , 1994, American journal of hematology.

[14]  Jason H. Moore,et al.  Gene expression signatures for autoimmune disease in peripheral blood mononuclear cells , 2004, Arthritis research & therapy.

[15]  T. Ortel,et al.  Clinical and laboratory evaluation of thrombophilia. , 2003, Clinics in chest medicine.

[16]  M. Greaves.  Antiphospholipid antibodies and thrombosis , 1999, The Lancet.

[17]  L. Melton,et al.  The Epidemiology of Venous Thromboembolism in the Community , 2001, Thrombosis and Haemostasis.

[18]  T. Barbui,et al.  Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. , 1999, Blood.

[19]  R. White,et al.  Incidence of Idiopathic Deep Venous Thrombosis and Secondary Thromboembolism among Ethnic Groups in California , 1998, Annals of Internal Medicine.

[20]  R. Roubey.  Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. , 1994, Blood.

[21]  R. Derksen,et al.  Lupus Anticoagulant Activity Is Frequently Dependent on the Presence of β2-Glycoprotein I , 1992, Thrombosis and Haemostasis.

[22]  M. West,et al.  Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Mackworth-Young,et al.  ANTICARDIOLIPIN ANTIBODIES: DETECTION BY RADIOIMMUNOASSAY AND ASSOCIATION WITH THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS , 1983, The Lancet.

[24]  T. Brighton,et al.  Antiphospholipid antibodies and thrombosis. , 1994, Bailliere's clinical haematology.

[25]  W A Wilson,et al.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. , 1999, Arthritis and rheumatism.

[26]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Jacob H Rand,et al.  The antiphospholipid syndrome. , 2003, Annual review of medicine.

[28]  M. Lockshin,et al.  Validation of the Sapporo criteria for antiphospholipid syndrome. , 2000, Arthritis and rheumatism.

[29]  P. D. de Groot,et al.  Lupus Anticoagulant is the Strongest Risk Factor for both Venous and Arterial Thrombosis in Patients with Systemic Lupus Erythematosus , 1996, Thrombosis and Haemostasis.

[30]  T. Barbui,et al.  Lupus Anticoagulant IgG's (LA) Are Not Directed to Phospholipids only, but to a Complex of Lipid-Bound Human Prothrombin , 1991, Thrombosis and Haemostasis.